Captopril Accord

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Captopril Accord

What is Captopril Accord?

Captopril Accord is a medication belonging to a group of drugs known as angiotensin-converting enzyme (ACE) inhibitors. It is primarily used to manage conditions affecting the cardiovascular system by influencing the way the body regulates blood pressure and fluid balance.

Mechanism of Action

The active substance, captopril, works by inhibiting the activity of an enzyme that produces angiotensin II. Angiotensin II is a potent chemical in the body that causes blood vessels to narrow and promotes the retention of salt and water. By reducing the production of this substance, Captopril Accord helps to:

  • Relax blood vessels, allowing blood to flow more easily.
  • Lower blood pressure, reducing the workload on the heart.
  • Improve cardiac efficiency, which is particularly relevant in the management of heart failure.

Clinical Uses

Captopril Accord is utilized in several clinical contexts related to heart and circulatory health. Its primary applications include:

  • Hypertension: The management of high blood pressure to help prevent long-term complications such as stroke or heart attack.
  • Heart Failure: Chronic management of the heart's pumping capacity, often used in combination with other treatments.
  • Post-Myocardial Infarction: Improving survival and heart function following a heart attack (myocardial infarction).
  • Diabetic Nephropathy: The treatment of kidney disease in patients with type 1 diabetes, as it can help slow the progression of kidney damage.

Regulatory References

  1. Captopril - StatPearls - NCBI Bookshelf
  2. The Renin-Angiotensin-Aldosterone System (RAAS)
  3. ACE Inhibitors Mechanism of Action - StatPearls - NIH

What side effects are possible with Captopril Accord?

Possible Side Effects and Safety Information

The safety profile for Captopril Accord, an ACE inhibitor, is organized by regulatory authorities into frequency bands and System-Organ Classes (SOC) to communicate potential adverse reactions. The most common adverse effect, officially listed by regulators, is a dry, non-productive cough.

Other effects classified as common in official documents include taste impairment (dysgeusia), dizziness, and gastrointestinal issues like nausea, vomiting, or diarrhea. Effects classified as uncommon include hypotension (low blood pressure) and conditions like tachycardia.


Documented Serious Adverse Reactions

The official labeling highlights specific serious adverse reactions. The most notable is Angioedema, which involves rapid swelling of the face, tongue, or larynx and is classified as uncommon. Furthermore, Captopril is associated with a risk of Fetal Toxicity when used during the second and third trimesters of pregnancy, a constraint highlighted in regulatory documents.

Less frequently, blood disorders such as Neutropenia (a reduction in white blood cells) have been reported, primarily in patients with pre-existing conditions like renal impairment or collagen vascular disease. Hepatic failure progressing from cholestatic jaundice is also classified as a very rare risk.


Population and Exposure Safety Notes

The regulatory profile notes that symptomatic hypotension is more likely to occur at the initiation of treatment or during dose increases. Safety constraints exist for certain populations: patients with renal impairment face an increased risk of hyperkalaemia (high potassium) and specific blood disorders. The risk of significant hypotension is also elevated in patients with existing volume or sodium depletion, as defined in official prescribing information.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Captopril overdose documents severe manifestations of excessive lowering of blood pressure. Documented overdose presentations include severe hypotension, which can rapidly progress to shock, as well as lethargy and bradycardia (abnormally slow heart rate). The most serious outcomes listed in regulatory documents involve the renal system, specifically renal failure and electrolyte disturbance.

Immediate actions are mandated by regulators for any suspected overdose: individuals must seek emergency medical attention or call the Poison Help line. Urgent medical help is required immediately if the affected person has collapsed, had a seizure, is having trouble breathing, or cannot be awakened. Treatment is defined as entirely symptomatic and supportive, as no specific chemical antidote is generally listed in official documentation. Supportive management includes placing the patient in a supine position and administering fluids and sodium supplements; elimination procedures like haemodialysis are also documented as a possible measure.

Therapeutic Uses of Captopril Accord

Captopril Accord is generally used in situations involving certain distressing symptoms across cardiovascular and renal therapeutic domains. This medication is commonly applied in addressing high blood pressure, heart failure, and conditions presenting with systemic or localized discomfort. Its use is also considered relevant for patients following a heart attack, where it may assist with maintaining functional stability and supports the patient during difficult episodes.

Captopril is used across conditions presenting with acute episodes, such as those involving diabetic nephropathy (a form of kidney disease), where symptoms may intensify temporarily. It contributes to easing the overall symptom load associated with symptoms linked to organ-specific functional stress. Captopril provides supportive relief when symptoms interfere with routine activities, helping patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.

Quick Fact: Relief for Symptoms that Create Noticeable Physiological Strain

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Captopril Accord is officially designated for use in adult patients diagnosed with conditions such as hypertension, heart failure, post-myocardial infarction left ventricular dysfunction, and diabetic nephropathy. The eligibility profile is defined by official regulatory exclusions and limitations.


Populations Who Must Not Use

The medicine is strictly contraindicated and must not be used by specific populations according to regulatory labeling. This includes individuals with a known hypersensitivity to Captopril or any other ACE inhibitor, or anyone with a history of angioedema (serious swelling), whether hereditary or previously linked to an ACE inhibitor. Use is also prohibited during the second and third trimesters of pregnancy due to the risk of fetal harm. Additionally, Captopril Accord must not be taken concurrently with Aliskiren in diabetic or renally impaired patients, or with Sacubitril/Valsartan.


Restricted or Conditional Use

Specific clinical states and patient groups require special consideration. The medicine is generally not recommended during the first trimester of pregnancy or for mothers breastfeeding a newborn or premature infant. Caution is necessary for patients with impaired renal function or hepatic impairment, as well as those with certain heart valve or renal artery conditions. Furthermore, the safety and efficacy of Captopril Accord have not been established for the general pediatric population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Category Official Regulatory Statement
Medicinal product categories with documented interactions Angiotensin Receptor Blockers, Direct Renin Inhibitors, Neprilysin Inhibitors, Potassium-sparing Diuretics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Other Antihypertensive Agents, Immunosuppressive agents, Antacids.
Specific interacting medicines (if explicitly listed) Aliskiren, Sacubitril/Valsartan, Lithium, Potassium Supplements, Injectable Gold.
Mechanistic basis of interactions (only if stated in label) Dual Inhibition of the Renin-Angiotensin System (RAS); Pharmacodynamic synergism (additive hypotensive effects); Altered electrolyte balance leading to hyperkalemia; Decreased absorption (pharmacokinetic effect of food/antacids).
Timing-based interaction rules (if applicable) Must be administered one hour before meals to avoid reduced absorption. Prohibited within 36 hours of discontinuing Sacubitril/Valsartan.
Population-specific interaction notes (if applicable) Co-administration with Aliskiren is contraindicated in patients with diabetes or moderate-to-severe renal impairment.
Interaction-related restrictions Prohibited co-administration with Sacubitril/Valsartan and Aliskiren in specific populations.

Resulting Interaction Structure

Official interaction statements:

  • The use is contraindicated with Sacubitril/Valsartan; a 36-hour separation period is mandatory upon switching therapies.
  • Co-administration with Aliskiren is contraindicated in patients with diabetes or pre-existing kidney dysfunction.
  • Potassium-sparing diuretics, potassium supplements, or potassium-containing salt substitutes increase the documented risk of hyperkalemia.
  • NSAIDs may reduce the antihypertensive effect and increase the risk of worsening kidney function.
  • Lithium co-administration is associated with increased serum concentrations and documented toxicity risk.
  • Food and antacids decrease the absorption, hence the required timing separation (one hour before meals).

Connection to the overall interaction profile (2–4 sentences):

The regulatory documents establish the Captopril interaction profile by defining explicit prohibitions and mandatory timing rules to manage both pharmacokinetic and pharmacodynamic risks. This structure details interactions leading to altered potassium levels and significant additive blood pressure-lowering effects. The official documentation includes distinct warnings for heightened interaction severity specifically within defined patient populations.

Mechanism of Action

Captopril Accord functions as a competitive inhibitor of the somatic Angiotensin-Converting Enzyme (ACE), also known as kininase II. This zinc metallopeptidase is primarily located on the luminal surface of the vascular endothelium throughout the systemic circulation, particularly in the pulmonary bed.

The drug's sulfhydryl moiety binds to the active site of the enzyme, blocking the enzymatic cleavage of the decapeptide Angiotensin I into the octapeptide Angiotensin II in the plasma and tissues. The resulting reduction in circulating and local Angiotensin II concentration leads to two primary downstream cascades:

  1. Reduced Angiotensin II-mediated signaling: Decreased agonism at the Angiotensin II Type 1 (AT1) receptors on vascular smooth muscle cells results in diminished inositol triphosphate (IP3) and diacylglycerol (DAG) signaling, ultimately modulating intracellular calcium release and promoting vasodilation via reduced smooth muscle contraction.
  2. Decreased Aldosterone Secretion: Reduced Angiotensin II action diminishes its stimulus on the adrenal cortex, leading to decreased secretion of Aldosterone. This results in modulated sodium and water reabsorption in the distal tubules and collecting ducts of the renal nephron.

Simultaneously, ACE inhibition impedes the degradation of the vasoactive peptide Bradykinin, leading to its local accumulation. Bradykinin accumulation contributes to the overall system-level physiological consequence of reduced systemic vascular resistance and modulated extracellular fluid volume.

Dosage and Administration Information

How to Use Captopril Accord

Captopril Accord is administered via the oral route as a tablet, with the use protocol governed by established clinical guidelines. The critical instruction for administration is that the tablet must be taken on an empty stomach, specifically one hour before meals, because food can significantly reduce the absorption of the medicine by 30 to 40 percent.

The dosage is typically distributed across two or three separate administrations daily (BID or TID), a frequency pattern applied across approved adult indications. Treatment is initiated with a low starting dose—such as 6.25 mg to 12.5 mg for heart failure or 25 mg for hypertension—and is then titrated gradually over intervals of one to two weeks, as described in prescribing information, to reach the appropriate maintenance level.

Official Dosing Framework Summary

Indication Typical Starting Dose Range General Maintenance Dose Range
Hypertension 25 mg to 50 mg daily (divided) Up to 150 mg daily (divided)
Heart Failure 6.25 mg to 12.5 mg TID 75 mg to 150 mg daily (divided)

Population-Specific Use

Official instructions require the initial dose to be reduced and the dosing interval possibly prolonged for patients presenting with impaired kidney function, acknowledging the drug's primary elimination pathway. Treatment initiation for certain high-risk conditions, such as post-myocardial infarction and heart failure, is required to occur under close medical supervision.

Recent Clinical Evidence

Captopril Accord: Recent Clinical Evidence

This overview summarizes the key clinical findings related to the use of captopril, the active ingredient in Captopril Accord, as reported in contemporary research and meta-analyses. The findings center on its established uses in managing cardiovascular and renal conditions.


Management of Hypertension

Research continues to affirm the role of captopril in the management of essential hypertension. Studies have evaluated the effects of captopril, alone or in combination with diuretics, on blood pressure reduction. Clinical trials suggest that captopril may be associated with changes in both systolic and diastolic blood pressure. Its use is often initiated to manage high blood pressure, particularly when early intervention is warranted. The response rate and magnitude of effect have been examined across various patient demographics.


Post-Myocardial Infarction Use

Captopril has been investigated for its potential role following a myocardial infarction (heart attack). Clinical trials reported its use in patients who are hemodynamically stable post-MI, particularly those with or without left ventricular dysfunction. Evidence suggested that early initiation of captopril may be associated with an improvement in outcomes, including a change in the risk profile for future cardiovascular events. The effects were observed in patients across a spectrum of ages.


Impact on Diabetic Nephropathy

Research has examined the relationship between captopril use and diabetic nephropathy in patients with Type 1 diabetes. Studies reported that captopril may be associated with a decrease in the rate of progression of kidney dysfunction, indicated by changes in proteinuria. These studies evaluated the drug's effect beyond simple blood pressure control, focusing on the preservation of kidney function over extended periods of time.

Key Studies & References Captopril - StatPearls (NCBI Bookshelf)

Frequently Asked Questions (FAQ)

Common questions about Captopril Accord (FAQ)

Q: Is Captopril Accord the same kind of medicine as lisinopril or enalapril?

A: Captopril Accord is classified as an Angiotensin-Converting Enzyme (ACE) inhibitor. According to official drug information, this is the same pharmacological class of medicine as both lisinopril and enalapril.

Q: What is the main difference between Captopril Accord and other blood pressure pills?

A: Captopril belongs to the ACE inhibitor class of blood pressure medicines. It is distinguished from some other similar drugs because it is pharmacologically active immediately upon ingestion and does not require the body to perform a chemical transformation to start working.

Q: Does Captopril Accord start working immediately after I take it?

A: The medicine is rapidly absorbed, with peak levels in the blood reaching their maximum about one hour after oral administration. Official information indicates that a noticeable drop in blood pressure may start to occur within 60 to 90 minutes after taking a dose.

Q: How long does it take to see the full effect of Captopril Accord on blood pressure?

A: While the medicine begins working quickly, it may take one to two weeks of continuous use to observe more consistent changes in blood pressure. Official instructions mention that doses are adjusted gradually by a healthcare professional over intervals of one to two weeks to reach the appropriate maintenance level.

Q: What does it mean if my cough gets worse while taking Captopril Accord?

A: Official documents describe a dry, non-productive cough as a common side effect of Captopril. If any side effect becomes a concern, including a persistent cough, it is typically addressed by a healthcare professional.

Q: Do I need to avoid any specific foods or drinks while using Captopril Accord?

A: Regulatory documents describe the requirement that Captopril Accord be taken on an empty stomach, one hour before meals, due to food significantly reducing its absorption. There are also warnings that potassium-containing salt substitutes and certain high-potassium foods can increase the documented risk of high potassium levels (hyperkalemia).

Q: Can taking Captopril Accord cause problems with my kidneys over time?

A: The medicine is associated with both specific clinical uses and noted cautions related to the kidneys. Studies have examined its use in specific kidney problems caused by diabetes. However, regulatory information also notes a risk of worsening kidney function or high potassium, especially in people with pre-existing kidney issues.

Q: Why are regular blood tests sometimes needed when a person takes Captopril Accord?

A: Official product information indicates that blood tests may be recommended to monitor kidney function and key markers. The tests are intended to monitor key indicators, including potassium levels (due to hyperkalemia risk) and white blood cell counts (due to neutropenia risk).

Q: How is Captopril Accord different from a beta-blocker medicine?

A: Captopril is an ACE inhibitor, which works by intervening in the body's pressure regulation system (RAAS) to promote blood vessel relaxation. Beta-blockers are a different class of medicine that works by blocking the effects of adrenaline on the heart. Both are used to manage blood pressure but function through distinct mechanisms.

Q: Does Captopril Accord make people feel tired or fatigued?

A: Excessive tiredness or fatigue is listed as a potential side effect in some official drug information summaries.

Q: What are the concerns about Captopril Accord and women who might become pregnant?

A: The medicine is strictly prohibited for use during the second and third trimesters of pregnancy due to the risk of fetal harm. Official information notes that women who are or plan to become pregnant should inform their healthcare professional.

Q: Is Captopril Accord safe for people with diabetes?

A: Official documents state that Captopril is indicated for treating kidney problems caused by Type 1 diabetes (diabetic nephropathy). However, its co-administration with another drug, Aliskiren, is strictly contraindicated in diabetic patients.

Q: Is Captopril Accord safe for use in older adults (seniors)?

A: Use in this population is described as requiring caution. This is particularly true when it is combined with certain other medicines, such as NSAIDs and diuretics, due to the potential for an increased risk of specific side effects in older adults.

Q: Can Captopril Accord be taken if someone already has existing kidney problems?

A: Official information describes use in this population as requiring caution. Regulatory instructions require that patients with impaired kidney function receive a reduced initial dose. This caution is due to the increased risk of high potassium and specific blood disorders in this population.

Q: What should be done if a dose of Captopril Accord is forgotten?

A: Official regulatory guidance describes a protocol for missed doses: the missed dose is taken as soon as it is remembered, unless it is almost time for the next dose, in which case the missed dose is skipped. The guidance specifies that double doses are not to be taken.

Q: Why is Captopril Accord sometimes described as a 'sulfhydryl group-containing' ACE inhibitor?

A: Captopril is described this way because it contains a sulfhydryl moiety (a specific chemical component). Official documents explain that this particular part is what binds to the Angiotensin-Converting Enzyme to block its function.

Q: Are there different brand names for the medicine Captopril?

A: Yes, Captopril is the name of the active ingredient. Capoten is one of the brand names associated with the active ingredient Captopril.

Q: How long does Captopril Accord stay in the body after the last dose?

A: The apparent elimination half-life for the unchanged captopril compound is approximately two hours. Official information notes that retention of the drug may occur in patients who have impaired kidney function.

Q: Can Captopril Accord cause issues with sodium or salt levels in the body?

A: Yes, Captopril can affect salt balance. Its mechanism of action leads to a reduction of aldosterone, which causes sodium and fluid loss. This action may also be associated with small increases in serum potassium levels.

Q: What is the risk of angioedema (swelling) when taking Captopril Accord?

A: Angioedema, a serious reaction involving rapid swelling of the face, tongue, or throat, is classified as an uncommon serious adverse reaction in the official safety profile. Regulatory documents indicate that this swelling can occur at any time while taking the medicine.

Q: Is Captopril Accord the preferred ACE inhibitor for people who have liver issues?

A: Official documents do not rank or define Captopril as the 'preferred' ACE inhibitor for patients with liver issues. However, the official prescribing information does require caution for patients with hepatic impairment and notes that hepatic failure is a very rare associated risk.

Q: Does Captopril Accord need to be taken at a specific time of day?

A: While the total daily dose is typically divided across two or three administrations, the critical instruction is not the time of day but the timing relative to food. The tablet must be taken on an empty stomach, one hour before meals, to ensure proper absorption.

Q: What happens if Captopril Accord is suddenly stopped without consulting a professional?

A: The official stance notes that therapy should not be discontinued or interrupted unless directed by a clinician. Regulatory information has noted that abrupt withdrawal of Captopril has not been associated with a sudden or rapid increase in blood pressure.

Q: Why is it important to check blood pressure regularly when taking Captopril Accord?

A: Regular blood pressure monitoring is necessary to check for initial symptomatic low blood pressure (hypotension). It is also required as part of the gradual process of dose adjustment (titration) until the appropriate blood pressure level is reached.

Q: Can taking Captopril Accord affect the results of a routine blood test?

A: Yes, the medicine can affect routine blood test results, specifically concerning electrolyte balance and cell counts. These effects include the risk of high potassium (hyperkalemia) and potential changes in white blood cell counts (neutropenia).

Q: Do people typically need to take Captopril Accord for the rest of their lives for high blood pressure?

A: Captopril is used to help control high blood pressure, but it does not cure the condition. For this reason, official information indicates that medicine used to manage chronic high blood pressure may need to be taken for an extended period.

Q: Is it normal for Captopril Accord to cause a headache when starting the medication?

A: Headache is listed as a potential side effect in some official drug information summaries.

Q: Are the side effects of Captopril Accord temporary or do they last for the whole time using the drug?

A: Some effects, like symptomatic low blood pressure, are noted as being more likely at the initiation of treatment or during dose increases. Other common side effects, such as the dry cough, may persist for an extended period after the medicine is stopped.

Q: Are there any activities or situations that should be limited due to Captopril Accord?

A: Official information notes that due to the potential for dizziness or lightheadedness, caution may be necessary when operating heavy equipment or driving a motor vehicle. Official guidance also notes that adequate fluid intake may be considered to prevent volume depletion, which is associated with worsened dizziness.

Q: What is the evidence regarding Captopril Accord's use in people with scleroderma?

A: Studies have investigated and supported the use of Captopril in the management of scleroderma renal crisis, a serious complication of the condition. Evidence suggests a favorable response has been observed in some patients.

Q: Is Captopril Accord effective for heart protection even in people without high blood pressure?

A: The medicine is indicated for use in stable patients with left ventricular dysfunction following a myocardial infarction (heart attack). Studies in this population have examined its use in relation to survival and the incidence of heart failure, regardless of an existing hypertension diagnosis.

How should Captopril Accord be stored and disposed of?

How to Store and Dispose of Captopril Accord?

The official storage and disposal guidelines for Captopril are based on maintaining the medicine's stability and ensuring patient safety.

Official Storage Requirements

Condition Requirement
Temperature Do not store above 30 C. Do not refrigerate or freeze.
Protection Keep the container tightly closed to protect from moisture. Store in the original package to protect the medicine from light.
Safety Keep Captopril out of the reach and sight of children in a child-resistant container.
Stability Captopril Oral Solution must be used within 28 days after first opening.

Disposal Instructions

To dispose of Captopril that is no longer needed, patients should consult a healthcare professional, pharmacist, or local waste disposal company for guidance on proper disposal methods. Do not flush unused medication down the toilet unless specifically instructed to do so.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Captopril Accord found in:

A-Z Index: